Abstracts tagged "Sjögren’s Syndrome"

Abstract Number: 1917 • ACR Convergence 2020
In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with anti-cN1A Antibody Independently of the Myositis Subgroups
Dan Lévy¹, Benoit Nespola², Margherita Giannini³, Renaud Felten⁴, Francois Severac³, Coralie Varoquier³, Marina Rinagel³, Anne-Sophie Korganow⁵, Vincent Poindron⁵, Thierry Martin⁵, Julien Campagne⁶, Hassam Chereih⁷, Bastien Bouldoires⁸, Baptiste Hervier⁹, Cédric Lenormand³, Emmanuel Chatelus³, Laurent Arnaud¹⁰, Bernard Gény³, Jean Sibilia⁴, Jacques-Eric Gottenberg¹¹ and Alain Meyer¹², ¹CHU Strasbourg, CH, ²Department of Immunobiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³CHU Strasbourg, Strasbourg, ⁴Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ⁵Department of Clinical Immunology and Internal Medicine, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁶Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ⁷CH Pontarlier, Pontarlier, ⁸HP Colmar, Colmar, ⁹APHP Paris, Paris, ¹⁰Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ¹¹Strasbourg University Hospital, Strasbourg, France, ¹²Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France
Background/Purpose: Myositis are characterized by weakness and muscle inflammation. They encompass heterogeneous conditions, which include dermatomyositis (DM), inclusion body myositis (IBM) and polymyositis (PM) according…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].